Director, Global Patient Safety Pharmacoepidemiology
Eli Lilly and Company
I am a PhD epidemiologist with 20+ years of diverse research experience in the pharmaceutical industry spanning all phases of drug development from pre-clinical to post-marketing. My expertise includes designing and executing real world evidence (RWE) observational studies for both reimbursement (health outcomes) and regulatory (pharmacoepidemiology) purposes. I am a recognized subject matter expert in the design of studies using secondary data and have many publications in this space. I am the principal scientist responsible for several post-authorization safety studies executed as commitments to regulatory bodies globally. I am passionate about epidemiology, real world evidence research and study design/method development.